Stay Connected
Join us on Facebook Follow us on linked in Follow us on YouTube Follow us on Vimeo
Medical Device Pre-Market Case Study
Medpace Medical Device - Case Study


Want to learn more about the Medpace difference for medical device studies? Simply fill out this form and we will contact you.


Offices

Medpace Medical Device
3787 95th Avenue
Suite 100
Blaine, MN 55014 USA
Tel: +1.612.234.8500
Fax: +1.612.234.8501

Medpace Medical Device B.V.
Maastrichterlaan 127-129
NL – 6291 EN Vaals
Tel: +31.43.306.3320
Fax: +31.43.306.3338

MMD E-mail: info.mmd@medpace.com

MEDICAL DEVICE



VIEW NOW View now


  • Fact Sheet: MMD Overview
  • Fact Sheet: Cardiovascular
  • Fact Sheet: Ophthalmic
  • Fact Sheet: Orthopedic

  • Pre-market:
    Accelerating submission and approval

    This small medical device company, seeking FDA approval for a non-implantable cardiac device, partnered with Medpace Medical Device for this full-service study that spanned protocol design strategy through preparation and submission of the final 510(k) report.

    Challenges

    The device itself posed a unique challenge, because it was a novel device that would only be available in a limited number of hospitals and few physicians had ever worked with it. To identify, treat and follow up with subjects, multiple subspecialties within cardiology had to be involved in the study—including interventional cardiologists and electrophysiologists—creating scheduling difficulties and more challenging communication paths among the cardiologists and with the study team.

    Solution

    The study was conducted in the United States and United Kingdom, at 13 sites, involving 206 subjects. MMD ensured the study coordinators had all of the tools they needed to navigate scheduling and communication challenges. The physicians were trained by sponsor staff, with device simulators and the MMD operations team worked closely with the sponsor to address any additional training needs.

    Result

    • The study was two years in duration from initial discussions to final submission, and the 510(k) was submitted at an accelerated 48 days after last patient out, significantly outpacing the typical 90-120 days for submission
    • The initial clinical and regulatory strategy was developed to ensure the data could be used for multiple country submissions and the data from this study was used to obtain CE Mark and Health Canada approval